The Authority could not identify a dietary intake of monacolins from red yeast rice that does not give rise to concerns about harmful effects to health, for the general population, and as appropriate, for vulnerable subgroups of the population. As there is still a possibility of harmful effects on health associated with the use of monacolins from red yeast rice, but scientific uncertainty in this regard persists, and considering that monacolins from red yeast rice may only be used in food supplements and that the extent of use of those food supplements could not be determined by the Authority, the use of monacolins from red yeast rice in food supplements should be placed under Union scrutiny and therefore, should be included in Part C of Annex III to Regulation (EC) No 1925/2006. Considering the uncertainties outlined by the Authority in its scientific opinion and considering the statements given by interested parties on the safety profile of monacolins from red yeast rice, those interested parties have under Article 8(4) of Regulation (EC) No 1925/2006 the possibility to submit data demonstrating the safety of monacolins from red yeast rice to the Authority in accordance with Article 5 of Implementing Regulation (EU) No 307/2012. In accordance with Article 8(5) of Regulation (EC) No 1925/2006 the Commission should take a decision within four years from the entry into force of this Regulation, whether to list monacolins from red yeast rice in Annex III, Part A or Part B, as appropriate, taking into account the opinion of the Authority on any submitted data.
Recital 18, Regulation (EU) 2022/860
In forcesince 1 Jun 2022